Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 4:38 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 2,406 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dysplasia Mild Clear all
Terminated Phase 2 Interventional Results available

A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities

NCT03639987
View directory record Official record
Conditions
Cognitive Dysfunction, Alzheimer's Disease
Interventions
Aducanumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Nov 1, 2026, 4:38 AM EST
Completed Not applicable Interventional

Effect of Myofunctional Therapy on OSA

NCT04608552
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
OMT Exercises, Nasal Breathing Exercises, Use of Nasal Lavage
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Nov 1, 2026, 4:38 AM EST
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

MIBG in Aging and Neurologic Disorders

NCT05514106
View directory record Official record
Conditions
Lewy Body Disease, Dementia, Parkinsonism, Mild Cognitive Impairment, REM Sleep Behavior Disorder
Interventions
meta-iodobenzylguanidine (MIBG) (123I), 123I-MIBG scintigraphy
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 1, 2026, 4:38 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Radiofrequency Hyperthermia Safety Study

NCT05399771
View directory record Official record
Conditions
Chronic Pain, Soft Tissue Injuries, Wound Heal, Blood Flow
Interventions
Laser Doppler, Radiofrequency Heating System, Thermal Imaging, Healthcare Questionnaire & Measurement
Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Nov 1, 2026, 4:38 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease

NCT05138848
View directory record Official record
Conditions
Alzheimer Disease, Late Onset, Mild Cognitive Impairment, Sleep, Cognitive Change, Amyloid
Interventions
Time in Bed Restriction, Sleep Schedule
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years to 85 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 1, 2026, 4:38 AM EST
Completed Not applicable Interventional

Clinical Effectiveness of Self-Management Education Post-Mild Stroke

NCT01770184
View directory record Official record
Conditions
Stroke, Chronic Disease
Interventions
Chronic Disease Self-Management Program (CDSMP)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 90 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Nov 1, 2026, 4:38 AM EST
Completed Phase 3 Interventional

Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults

NCT05203315
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Duobrii 0.01 % / 0.045 % Topical Lotion, CeraVe, Topical Cream
Drug
Lead sponsor
Austin Institute for Clinical Research
Network
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Houston, Texas • Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Nov 1, 2026, 4:38 AM EST
Completed Phase 4 Interventional

EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)

NCT00230568
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aricept
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
35
States / cities
Phoenix, Arizona • El Centro, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2011 · Synced Nov 1, 2026, 4:38 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain Injury

NCT05337774
View directory record Official record
Conditions
Mild Traumatic Brain Injury
Interventions
[18F]PI-2620
Drug
Lead sponsor
Life Molecular Imaging SA.
Industry
Eligibility
25 Years to 54 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Nov 1, 2026, 4:38 AM EST
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

NCT00893789
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Armodafinil, Placebo
Drug · Other
Lead sponsor
Cephalon, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
68
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Nov 1, 2026, 4:38 AM EST
Completed Phase 1 Interventional

Study Mild Intermittent Asthma to Assess the Topical Safety and Tolerability of Albuterol Sulfate Acu-30™ DPI

NCT00565591
View directory record Official record
Conditions
Allergic Asthma
Interventions
Albuterol sulfate
Drug
Lead sponsor
Respirics Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 15, 2008 · Synced Nov 1, 2026, 4:38 AM EST
Completed Phase 2 Interventional Results available

Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)

NCT01595646
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Saline, Insulin detemir, Insulin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 89 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Nov 1, 2026, 4:38 AM EST
Completed Phase 2 Interventional Results available

Mild Encephalopathy in the Newborn Treated With Darbepoetin

NCT03071861
View directory record Official record
Conditions
Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy Mild
Interventions
Darbepoetin Alfa, Normal Saline
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
1 Hour to 24 Hours
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Nov 1, 2026, 4:38 AM EST
Completed Phase 1 Interventional

Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease

NCT01716637
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Etanercept, Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.
Biological · Dietary Supplement
Lead sponsor
Life Extension Foundation Inc.
Other
Eligibility
60 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Coral Springs, Florida • Delray Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Nov 1, 2026, 4:38 AM EST
Withdrawn No phase listed Observational

Implementation of AIP Services for Older Adults With AD

NCT07361601
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 1, 2026, 4:38 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis

NCT06488742
View directory record Official record
Conditions
Dermatitis, Atopic, Pruritus
Interventions
3% kanuka oil
Other
Lead sponsor
Nexgen Dermatologics, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Nov 1, 2026, 4:38 AM EST
Terminated No phase listed Observational Accepts healthy volunteers

Mild Neurocognitive Disorder in HIV Infection of the Brain

NCT01547754
View directory record Official record
Conditions
HIV-Associated Cognitive Motor Complex
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Nov 1, 2026, 4:38 AM EST
Completed Phase 2 Interventional Results available

Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers

NCT00619645
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Nov 1, 2026, 4:38 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Brain Research Assessing Impacts of Neurophysiological Processing Speed Training in Veterans

NCT06217575
View directory record Official record
Conditions
Traumatic Brain Injury, Mild Traumatic Brain Injury, Aging, Cognitive Decline
Interventions
Alpha neurofeedback training, Visual Attention Training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Nov 1, 2026, 4:38 AM EST
Completed Phase 2 Interventional

Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation

NCT01581177
View directory record Official record
Conditions
Asthma
Interventions
Albuterol DPI 25 mcg/inh, Albuterol DPI 90 mcg/inh, Placebo DPI, Albuterol MDI 90 mcg/inh
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
4
States / cities
San Jose, California • Medford, Oregon • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Nov 1, 2026, 4:38 AM EST
Completed Phase 4 Interventional

Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis

NCT00460083
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Elidel(R) (pimecrolimus 1%), EpiCeram(R) -ceramide based barrier repair cream
Drug · Device
Lead sponsor
Ceragenix Pharmaceuticals
Industry
Eligibility
2 Years to 12 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
San Diego, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 6, 2008 · Synced Nov 1, 2026, 4:38 AM EST
Completed Not applicable Interventional Results available

Mild Cognitive Impairment and Obstructive Sleep Apnea

NCT01482351
View directory record Official record
Conditions
Obstructive Sleep Apnea, Mild Cognitive Impairment
Interventions
CPAP adherence intervention, Attention control intervention
Behavioral
Lead sponsor
George Mason University
Other
Eligibility
55 Years to 89 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Abington, Pennsylvania • Philadelphia, Pennsylvania • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Nov 1, 2026, 4:38 AM EST
Terminated Phase 2 Interventional

Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease

NCT04987294
View directory record Official record
Conditions
Hyperuricemia, Gout, Chronic Kidney Diseases
Interventions
ALLN-346, Placebo
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
17
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Sheffield, Alabama + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Nov 1, 2026, 4:38 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD

NCT05881239
View directory record Official record
Conditions
Subjective Cognitive Concerns, Mild Cognitive Impairment, Mild Behavioral Impairment, Healthy Aging
Interventions
AROMHA Brain Health Test
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Nov 1, 2026, 4:38 AM EST